Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desonide Ointment, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Ointment, 0.05%, of Perrigo New York, Inc. Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Desonide Ointment, 0.05%, has an estimated market size of $13 million for twelve months ending December 2018 according to IQVIA. Alembic has a cumulative total of 105 ANDA approvals (93 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1529.55 |
Dr. Reddys Lab | 6315.00 |
Cipla | 1423.40 |
Zydus Lifesciences | 1021.00 |
Lupin | 1679.75 |
View more.. |